Effect of neuromuscular electrical stimulation for fatigue management in patients with advanced laryngeal cancer receiving chemoradiotherapy

Mei-jia Zhang, MMa, Ji-wei Mu, MMd, Xiusheng Qu, MMD, Chong Feng, MMc, Wei Zhao, MMd,*

Abstract
This study retrospectively investigated the effect of neuromuscular electrical stimulation (NMES) for fatigue management in patients with advanced laryngeal cancer (ALC) receiving chemoradiotherapy.

A total of 60 eligible patients with ALC receiving chemoradiotherapy were included. These patients were assigned equally to a treatment group and a control group. Patients in the treatment group received NMES therapy and were treated for a total of 8 weeks, while the patients in the control group did not receive NMES therapy. The primary outcome was fatigue, measured by the multidimensional fatigue inventory (MFI). The secondary outcomes included anxiety and depression, measured by the Hospital Anxiety and Depression Scale (HADS), and sleep quality, measured by the Pittsburgh Sleep Quality Index (PSQI). All outcomes were evaluated before and after 8-week NMES treatment.

After 8-week NMES treatment, the patients in the treatment group did not exert better effect than patients in the control group in fatigue relief, measured by the MFI score, anxiety and depression decrease, assessed by HADS, and sleep quality improvement, evaluated by PSQI.

The results of this study demonstrate that NMES may not benefit for fatigue relief in patients with ALC receiving chemoradiotherapy. Future studies should still focus on this topic and warrant these results.

Abbreviations: ALC = advanced laryngeal cancer, HADS = Hospital Anxiety and Depression Scale, LC = laryngeal cancer, MFI = multidimensional fatigue inventory, NMES = neuromuscular electrical stimulation, NSCLC = nonsmall cell lung cancer, PSQI = Pittsburgh Sleep Quality Index, TEAS = transcutaneous electrical acupoint stimulation.

Keywords: advanced laryngeal cancer, effect, neuromuscular electrical stimulation

1. Introduction
Laryngeal cancer (LC) is one of the most common types of malignant tumors for human beings.[1–3] It has been reported that surgical treatment may be effective for patients with early LC.[4,5] However, patients are often difficult to achieve the desired results with advanced laryngeal carcinoma (ALC).[6,7]

Chemoradiotherapy is a primary intervention for the ALC, and it is reported that patients have 10% to 45% of 5-year overall survival.[8–10] Unfortunately, most patients receiving chemoradiotherapy often experience a variety of adverse effects.[11–13] These adverse effects often consist of fatigue, anemia, leukopenia, thrombopenia, nausea, vomiting, diarrhea, stomatitis, infection, and renal and hepatic toxicity.

Previous study reported that about 50% to 75% patients with cancers had experienced fatigue when they received such treatment.[14] It is also reported that such number increases to 80% to 96% for patients with cancer undergoing chemotherapy, and 60% to 93% for them also receiving radiotherapy.[15,16] Additionally, such condition can also result in anxiety, depression, and a very poor quality of life for those patients.[17,18] Unfortunately, very few interventions can effectively manage the condition of cancer-related fatigue.

Complementary and alternative therapy is reported to treat such condition effectively.[19,20] These interventions include acupuncture, acupressure, massage, moxibustion, yoga, Qigong, Tai Chi, and neuromuscular electrical stimulation (NMES).[21–30] Of those, NMES is one of the most potential management for decreasing cancer-related fatigue. However, no data is available to support that NMES can effectively manage this condition, especially specific in patients with ALC. Thus, in this retrospective study, we explored the potential effect of NMES for managing treatment-related fatigue in patients with ALC receiving chemoradiotherapy.

2. Methods and patients
2.1. Ethics
This study was approved by the Ethical Committees of First Affiliated Hospital of Jiamusi University, Second Affiliated Hospital of Jiamusi University, and Hongqi Affiliated Hospital of Mudanjiang Medical University. All patients provided signed informed consent in this study.
2.2. Design
This retrospective study was conducted between June 2016 and October 2017 at First Affiliated Hospital of Jiamusi University, Second Affiliated Hospital of Jiamusi University, and Hongqi Affiliated Hospital of Mudanjiang Medical University. It included 60 eligible patients with ALC receiving chemoradiotherapy. Of these patients, 30 patients in the treatment group received NMES, while the other 30 patients did not receive this intervention.

2.3. Participants
All patients aged between 18 and 70 years old were histologically confirmed diagnosis of ALC with squamous cell carcinoma. Additionally, patients were also needed to meet the clinical stages of III and IV diseases, according to the Union for International Cancer Control,[31] as well as the locations of all tumors in the glottis or supraglottis. Patients were excluded if they had cardiology diseases, metal embedded into the body around the利用ized points, abnormal functions of liver and kidney, severe systemic complications, mental disorder, and gestational or lactating. In addition, the patient cases were also excluded if they had incomplete data, and received therapies of electrical stimulations, such as NMES, electroacupuncture, and any others.

2.4. Management
All patients in the treatment group were administered NMES using NMES device (HANS-100, Nanjing Jisheng Medical Technology Co, Ltd, Nanjing, China) with a frequency of 2 to 100 Hz, at bilateral Zusanli (ST36),[32] 30 minutes each session, 1 session daily, 2 sessions weekly for a total of 8 weeks. The current intensity was gradually increased to the maximum tolerance of each individual subject. ST36 locates 3 cun below the lower border of the patella, and 1 finger width lateral from the anterior border of the tibia. The patients in the control group did not receive NMES treatment during the period of fatigue management with NMES in the control group.

2.5. Outcomes
The primary outcome included fatigue, measured by the multidimensional fatigue inventory (MFI).[13] It included 5 subscales, each scale varies from 0 to 20, with the lower score indicating the less degree of fatigue. The secondary outcomes consisted of anxiety and depression, measured by the Hospital Anxiety and Depression Scale (HADS),[34] and sleep quality, measured by the Pittsburgh Sleep Quality Index (PSQI).[35] The HADS scale consists of an anxiety subscale and a depression subscale, with 7 items in both subscales. Each scale rates from 0, indicating the worst status, to 3, best status. The HADS scale ranges from 0 to 21, with a lower score denoting a better sleep quality. All outcomes were evaluated before and after 8-week NMES treatment.

2.6. Statistical analysis
All baseline and outcome data were analyzed by using SAS package 9.2 (SAS Institute Inc, Cary, NC). Continuous data was analyzed by the t test or Mann–Whitney rank sum test. Categorical data was analyzed by the Pearson χ² test or Fisher exact test. \( P < .05 \) was set as the statistical significance level.

3. Results
The characteristics of all 60 eligible patients with ALC are summarized in this retrospective study (Table 1). There were not significant differences in all characteristics between 2 groups before the study.

After 8-week NMES treatment, patients in the treatment group neither showed better outcomes in cancer-related fatigue relief, as measured by MFI scale (general fatigue, \( P = .64; \) physical fatigue, \( P = .23; \) activity, \( P = .15; \) motivation, \( P = .24; \) mental fatigue, \( P = .23; \) Table 2), nor the anxiety (\( P = .23, \) Table 3) and depression (\( P = .38, \) Table 3) relief, assessed by the HADS scale, as well as the sleep quality improvement, evaluated by the PSQI scale (\( P = .59; \) Table 3).

| Table 1 Characteristics of all included patients at baseline. |
|---------------------------------------------------------------|
| **Characteristics** | **Treatment group** | **Control group** | **P value** |
| Sex                          | Age, y | 64.2 (0.8) | 63.9 (10.6) | .91 |
| Race (Han ethnicity) | Male | 21 (70.0) | 17 (66.7) | .29 |
| | Female | 9 (30.0) | 13 (43.3) | .29 |
| Marital status | Married | 24 (80.0) | 26 (86.7) | .49 |
| | Divorced/widowed | 6 (20.0) | 4 (13.3) | .49 |
| Performance status | 0 | 10 (33.3) | 13 (43.3) | .43 |
| | 1 | 20 (66.7) | 17 (56.7) | .43 |
| Location | Supra glottis | 14 (46.7) | 15 (50.0) | .80 |
| | Vocal cord | 16 (53.3) | 15 (50.0) | .80 |
| T category | T1 | 2 (6.7) | 3 (10.0) | .64 |
| | T2 | 4 (13.3) | 2 (6.7) | .40 |
| | T3 | 18 (60.0) | 21 (70.0) | .42 |
| | T4 | 6 (20.0) | 4 (13.3) | .49 |
| N category | N0 | 23 (76.7) | 21 (70.0) | .56 |
| | N1 | 2 (6.7) | 3 (10.0) | .64 |
| | N2 | 4 (13.3) | 4 (13.3) | 1.00 |
| | N3 | 1 (3.3) | 2 (6.7) | .56 |
| Disease stage | III | 18 (60.0) | 20 (66.7) | .59 |
| | IV | 12 (40.0) | 10 (33.3) | .59 |
| MFI scale | General fatigue | 17.4 (3.0) | 17.1 (3.1) | .70 |
| | Physical fatigue | 16.1 (2.9) | 16.3 (2.6) | .78 |
| | Activity | 14.8 (3.0) | 15.0 (3.2) | .80 |
| | Motivation | 13.3 (3.7) | 13.5 (3.9) | .84 |
| | Mental fatigue | 14.2 (3.1) | 14.5 (3.4) | .72 |
| HADS-Anxiety | 6.9 (2.9) | 7.0 (3.1) | .90 |
| HADS-Depression | 7.2 (3.3) | 7.1 (3.1) | .90 |
| PSQI-Sleep quality | 9.0 (3.7) | 8.8 (4.0) | .84 |
| Radiotherapy | 30 (100.0) | 30 (100.0) | 1.00 |
| Chemotherapy | Cisplatin | 15 (50.0) | 10 (33.3) | .19 |
| | Fluorouracil | 11 (36.7) | 7 (23.3) | .26 |
| | 5-Fluorouracil | 4 (13.3) | 5 (16.7) | .72 |
| | Paclitaxel | 4 (13.3) | 3 (10.0) | .69 |
| | Gemcitabine | 3 (10.0) | 4 (13.3) | .69 |

Note: Data are present as mean±standard deviation or number (%). HADS=Hospital Anxiety and Depression Scale, MFI=Multidimensional Fatigue Inventory, PSQI=Pittsburgh Sleep Quality Index.
4. Discussion

Previous related study explored the effectiveness of transcutaneous electrical acupoint stimulation (TEAS) therapy on cancer-related fatigue in patients with nonsmall cell lung cancer (NSCLC) after chemotherapy.[2,29] It found that chemotherapy may increase the fatigue in patients with NSCLC. Fortunately, TEAS can help relieve cancer related fatigue in those patients.[29]

Currently, no clinical study has explored the effect of NMES for managing treatment-related fatigue in patients with ALC receiving chemoradiotherapy. To the best of our knowledge, this study first investigated the effect of NMES for fatigue relief in patients with ALC undergoing chemoradiotherapy. The results of this study were inconsistent with the previous related study.[2,29]

The results of this first retrospectively study showed that NMES did not demonstrate promising outcomes in cancer-related fatigue relief, measured by MFI; anxiety and depression decrease; and sleep quality improvement in patients with ALC receiving chemoradiotherapy. It indicates that NMES may not benefit for cancer-related fatigue management in patients with ALC.

This study has several limitations. First, this study is a retrospective study, all the outcome data were just based on the current available data. Thus, no comprehensive outcome measurements were included in this study, such as outcome evaluation of voice rehabilitation. Second, the sample size in this study is quite small, which may affect the results of this study. Third, this study just assessed the outcome measurements after 8-week treatment, and no follow-up evaluations were utilized after the treatment. Thus, future studies should avoid the above limitations for further focus on this issue.

5. Conclusion

The results of this study demonstrated that NMES may not benefit the fatigue relief in patients with ALC receiving chemoradiotherapy.

Author contributions

Conceptualization: Wei Zhao, Mei-jia Zhang, Xiu-sheng Qu, Chong Feng.

Data curation: Wei Zhao, Mei-jia Zhang, Xiu-sheng Qu, Chong Feng.

Formal analysis: Ji-wei Mu.

Investigation: Chong Feng.

Methodology: Ji-wei Mu.

Project administration: Mei-jia Zhang.

Resources: Mei-jia Zhang.

Software: Ji-wei Mu.

Supervision: Wei Zhao, Mei-jia Zhang, Chong Feng.

Validation: Wei Zhao, Xiu-sheng Qu.

Visualization: Wei Zhao, Ji-wei Mu, Xiu-sheng Qu.

Writing – original draft: Wei Zhao, Mei-jia Zhang, Ji-wei Mu, Chong Feng.

Writing – review & editing: Wei Zhao, Mei-jia Zhang, Ji-wei Mu, Xiu-sheng Qu, Chong Feng.

References

[1] Britt CJ, Gourin CG. Contemporary management of advanced laryngeal cancer. Laryngoscope Investig Otolaryngol 2017;2:307–9.
[2] Garcia-León FJ, García-Estepa R, Romero-Tabares A, et al. Treatment of advanced laryngeal cancer and quality of life. Systematic review. Acta Otorrinolaringol Esp 2017;68:212–9.
[3] Salvador-Coloma C, Cohen E. Multidisciplinary care of laryngeal cancer. J Oncol Pract 2016;12:717–24.
[4] Mannelli G, Lazio MS, Luparello P, et al. Conservative treatment for advanced T3-T4 laryngeal cancer: meta-analysis of key oncological outcomes. Eur Arch Otorhinolaryngol 2018;275:27–38.
[5] Leone CA, Capasso P, Topazio D, et al. Supracricoid laryngectomy for recurrent laryngeal cancer after chemoradiotherapy: a systematic review and meta-analysis. Acta Otorhinolaryngol Ital 2016;36:439–49.
[6] Zhao X, Ji W. The application of extended supraglottic horizontal partial laryngectomy in advanced laryngeal carcinoma and vallecula carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2015;29:593–6.
[7] Eskuizmir G, Tanyeri Toker G, Çelik O, et al. Predictive and prognostic factors for patients with locoregionally advanced laryngeal carcinoma treated with surgical multimodality protocol. Eur Arch Otorhinolaryngol 2017;274:1701–11.
[8] Osborn HA, Hu A, Venkatesan V, et al. Comparison of endoscopic laser resection versus radiation therapy for the treatment of early glottic carcinoma. J Otolaryngol Head Neck Surg 2011;40:200–4.

[9] Zeng YC, Chi F, Xing R, et al. Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy. Jpn J Clin Oncol 2016;46:126–31.

[10] Zeng YC, Xue M, Chi F, et al. C-reactive protein level predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy. Tumour Biol 2012;33:891–5.

[11] Okami K, Hamano T, Takeo T, et al. Concurrent chemoradiotherapy with docetaxel for T2 laryngeal carcinoma. Tokai J Exp Clin Med 2008;33:130–4.

[12] Kouloulias V, Triantopoulou S, Vrouvas J, et al. Combined chemoradiotherapy with local microwave hyperthermia for treatment of T3N0 laryngeal carcinoma: a retrospective study with long-term follow-up. Acta Otorhinolaryngol Ital 2014;34:167–73.

[13] Ijichi K, Hanai N, Kawakita D, et al. Selection of therapeutic treatment with alternating chemoradiotherapy for larynx preservation in laryngeal carcinoma patients. Jpn J Clin Oncol 2014;44:1063–9.

[14] Stasi R, Abriani L, Beccaglia P, et al. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 2003;98: 1786–801.

[15] Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy. Cancer 2010;116:3513–20.

[16] Hofman M, Ryan JL, Figueroa-Moseley CD, et al. Cancer-related fatigue: the scale of the problem. Oncologist 2007;12(suppl):4–10.

[17] So W, Marsh G, Ling W, et al. The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study. Oncol Nurs Forum 2009;36:E205–214.

[18] Traeger L, Braun IM, Greer JA, et al. Parsing depression from fatigue in patients with cancer using the fatigue symptom inventory. J Pain Symptom Manage 2011;42:52–9.

[19] Bar-Sela G, Danos S, Visel B, et al. The effect of complementary and alternative medicine on quality of life, depression, anxiety, and fatigue levels among cancer patients during active oncology treatment: phase II study. Support Care Cancer 2015;23: 1979–1985.

[20] Jain S, Pavlik D, Distefan J, et al. Complementary medicine for fatigue and control variability in breast cancer survivors: a randomized controlled trial. Cancer 2012;118:777–87.

[21] Cheng CS, Chen LY, Ning ZY, et al. Acupuncture for cancer-related fatigue in lung cancer patients: a randomized, double blind, placebo-controlled pilot trial. Support Care Cancer 2017;25:3807–14.

[22] Molassiotis A, Sylt P, Diggins H. The management of cancer-related fatigue after chemotherapy with acupuncture and acupressure: a randomised controlled trial. Complement Ther Med 2007;15:228–37.

[23] Wyatt GK, Frambes DA, Harris RE, et al. Self-administered acupuncture for persistent cancer-related fatigue: fidelity considerations. Altern Ther Health Med 2015;21:18–23.

[24] Jacobs S, Mowbray C, Cates LM, et al. Pilot study of massage to improve sleep and fatigue in hospitalized adolescents with cancer. Pediatr Blood Cancer 2016;63:880–6.

[25] Kim M, Kim JE, Lee HY, et al. Moxibustion for cancer-related fatigue: study protocol for a randomized controlled trial. BMC Complement Altern Med 2017;17:353.

[26] Zhang LL, Wang SZ, Chen HL, et al. Tai Chi exercise for cancer-related fatigue in patients with lung cancer undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manage 2016;51:304–11.

[27] Larkey L, Huberty J, Pedersen M, et al. Qigong/Tai Chi Easy for fatigue in breast cancer survivors: rationale and design of a randomized clinical trial. Contemp Clin Trials 2016;50:222–8.

[28] Stan DL, Croghan KA, Croghan IT, et al. Randomized pilot trial of yoga versus strengthening exercises in breast cancer survivors with cancer-related fatigue. Support Care Cancer 2016;24:4035–15.

[29] Hou L, Zhou C, Wu Y, et al. Transcutaneous electrical acupoint stimulation (TEAS) relieved cancer-related fatigue in non-small cell lung cancer (NSCLC) patients after chemotherapy. J Thorac Dis 2017;9:1959–66.

[30] Lyon D, Kelly D, Walter J, et al. Randomized sham controlled trial of cranial microcurrent stimulation for symptoms of depression, anxiety, pain, fatigue and sleep disturbances in women receiving chemotherapy for early-stage breast cancer. Springerplus 2015;4:369.

[31] World Health Organization. National cancer control programmes. Policies and Managerial Guidelines for early-stage breast cancer. Springerplus 2015;4:369.